TRAVERE THERAPEUTICS INC
Travere Therapeutics (TVTX) is a biopharmaceutical company focused on treatments for rare kidney and other rare diseases, with particular emphasis on proteinuric kidney disorders. Investors should know Travere centres its strategy on a small portfolio of specialised programmes, with a lead candidate aimed at reducing proteinuria in conditions such as focal segmental glomerulosclerosis (FSGS) and IgA nephropathy. The company balances clinical development with efforts to commercialise therapies for niche patient populations; revenues and growth depend heavily on trial outcomes, regulatory decisions and uptake in specialist centres. As a mid-cap biotech (market cap roughly $2.48bn), the stock can be more volatile than large-cap pharmaceutical peers and sensitive to clinical newsflow and reimbursement dynamics. Potential upside comes from successful trial readouts and market adoption, while downside risks include clinical setbacks, regulatory delays and pricing pressure. This summary is for educational purposes only and is not personalised investment advice; consider consulting a financial adviser before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Travere Therapeutics' stock, expecting its value to rise to $42.07.
Financial Health
Travere Therapeutics is performing well with strong revenue and cash flow, although it has low book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring TVTX
Orphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published: August 20, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Clinical readouts and regulatory milestones can move the stock; these events offer potential upside but also carry clear binary risk.
Specialist Market Focus
Concentrating on rare kidney diseases may allow premium pricing and focused uptake in specialist centres, though patient‑population size limits scale.
Commercial & Reimbursement
Successful commercialisation depends on payer decisions and clinic adoption; reimbursement dynamics can materially affect revenue prospects.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.